Herein, we report the protein immobilization and stability studies of heterogeneous hollow mesoporous nanocapsules (Hhmn) for drug and protein delivery. The final results of the diverse precursors such as TEOS, TMOS, APTES, and zinc acetate on the formation of the hollow-mesoporous architecture of nanocapsules have been assimilated in this work. Three types of Hhmn of various sizes were synthesized. Among the three Hhmn, sample I and II nanocapsules were synthesized in the presence of zinc acetate and were identified to be amorphous in nature. Sample III nanocapsules synthesized in the absence of zinc acetate were analogous to the other two synthesized samples. Physiochemical analysis showed the formation of zinc phosphate in the silica matrix for the samples when synthesized with zinc acetate. Specific surface area analysis revealed that sample III has a relatively higher specific surface area. Further, the drug/dye loading and release capacity for the nanocapsules were studied using doxorubicin (DOX) and imatinib mesylate (IM) as model anticancerous drugs and rhodamine 6G as a model dye. Among the synthesized nanocapsules, sample III was shown to have a higher loading capacity for DOX (∼128 μg). From the release kinetic studies of drug/dye, sample III nanocapsules demonstrate a controlled release pattern of DOX and IM. Additionally, protein adsorption and stability studies of samples I and II revealed that the BSA adsorption capacity increases with the increase in the initial concentration of BSA. Furthermore, analysis of the release profiles of BSA and OVA leads to the conclusion that the heterogeneous nanocapsules show a higher loading capacity and sustained release pattern toward OVA. These properties of the nanocapsules highlight their path to immunological applications.

中文翻译：

---

通过印迹 CPMV 制备的异质 (SiO2/ZnO) 中空介孔纳米胶囊上的蛋白质固定化：药物递送和免疫学应用的可能性

在此，我们报告了用于药物和蛋白质递送的异质中空介孔纳米胶囊 ( Hhmn )的蛋白质固定化和稳定性研究。不同前体如 TEOS、TMOS、APTES 和醋酸锌对纳米胶囊中空介孔结构形成的最终结果已在这项工作中进行了同化。合成了三种不同大小的Hhmn。在这三个Hhmn，样品 I 和 II 纳米胶囊是在醋酸锌存在下合成的，并被鉴定为本质上是无定形的。在不存在乙酸锌的情况下合成的样品 III 纳米胶囊与其他两个合成样品类似。理化分析表明，当与醋酸锌合成时，样品的二氧化硅基质中形成了磷酸锌。比表面积分析表明，样品III具有相对较高的比表面积。此外，使用阿霉素 (DOX) 和甲磺酸伊马替尼 (IM) 作为模型抗癌药物和罗丹明 6G 作为模型染料研究了纳米胶囊的药物/染料负载和释放能力。在合成的纳米胶囊中，样品 III 显示出更高的 DOX 负载能力（~128 μg）。从药物/染料的释放动力学研究来看，样品 III 纳米胶囊表现出 DOX 和 IM 的控释模式。此外，样品 I 和 II 的蛋白质吸附和稳定性研究表明，BSA 吸附能力随着 BSA 初始浓度的增加而增加。此外，对 BSA 和 OVA 释放曲线的分析得出的结论是，异质纳米胶囊对 OVA 显示出更高的负载能力和持续释放模式。纳米胶囊的这些特性突出了它们通往免疫学应用的道路。对 BSA 和 OVA 释放曲线的分析得出的结论是，异质纳米胶囊对 OVA 显示出更高的负载能力和持续释放模式。纳米胶囊的这些特性突出了它们通往免疫学应用的道路。对 BSA 和 OVA 释放曲线的分析得出的结论是，异质纳米胶囊对 OVA 显示出更高的负载能力和持续释放模式。纳米胶囊的这些特性突出了它们通往免疫学应用的道路。